Clinical Usefulness of Serum CYFRA 21-1 in Patients with Colorectal Cancer

Nuclear Medicine and Molecular Imaging

Volumn 47, Issue 3, 2013, Pages 181-187

  Lee, Jai Hyuen ^a  

^a Dankook University   (South Korea)

Author keywords

CEA and CA 19 9; Colorectal cancer; CYFRA 21 1

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; FLUORODEOXYGLUCOSE F 18;

ADENOMATOUS POLYP; ADENOSQUAMOUS CARCINOMA; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CLASSIFICATION; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; COLITIS; COLLOID CARCINOMA; COLON MELANOSIS; COLORECTAL CANCER; COLORECTAL CARCINOMA; COLORECTAL DISEASE; COLORECTAL POLYP; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIVERTICULOSIS; FEMALE; HISTOLOGY; HUMAN; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

EID: 84883420535     PISSN: 18693474     EISSN: 18693482     Source Type: Journal    
DOI: 10.1007/s13139-013-0218-4     Document Type: Article

References (36)

1. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434: 843-50.
2. Sarikaya I, Bloomston M, Povoski SP, Zhang J, Hall NC, Knopp MV, et al. FDG-PET scan in patients with clinically and/or radiologically suspicious colorectal cancer recurrence but normal CEA. World J Surg Oncol. 2007;5: 64.
3. Fiocchi F, Iotti V, Ligabue G, Malavasi N, Luppi G, Bagni B, et al. Role of carcinoembryonic antigen, magnetic resonance imaging, and positron emission tomography-computed tomography in the evaluation of patients with suspected local recurrence of colorectal cancer. Clin Imaging. 2011;35: 266-73.
4. Lee JH, Park SG, Jee KN, Park DG, Namgung H, Song IH. Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level. Nucl Med Commun. 2010;31: 576-82.
5. Riedl CC, Akhurst T, Larson S, Stanziale SF, Tuorto S, Bhargava A, et al. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med. 2007;48: 771-5.
6. Sanli Y, Kuyumcu S, Ozkan ZG, Kilic L, Balik E, Turkmen C, et al. The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels. Ann Nucl Med. 2012;56: 551-8.
7. Chang AC, Warren LR, Barreto SG, Williams R. Differing serum cea in primary and recurrent rectal cancer-a reflection of histology? World J Oncol. 2012;3: 59-63.
8. Waisberg J, Contim-Neto L, Oliveira MSL, Matheus CO, Nagashima CA, Goffi FS. Determination of carcinoembryonic antigen levels in peripheral and draining venous blood in patients with colorectal carcinoma. Arq Gastroenterol. 2004;41: 88-92.
9. Booth S, King J, Leonard J, Dykes P. Serum carcinoembryonic antigen in clinical disorders. Gut. 1973;14: 794-9.
10. Loewenstein M, Zamcheck N. Carcinoembryonic antigen (CEA) levels in benign gastrointestinal disease states. Cancer. 1978;42: 1412-8.
11. van der Schouw YT, Verbeek AL, Wobbes T, Segers MF, Thomas CM. Comparison of four serum tumour markers in the diagnosis of colorectal carcinoma. Br J Cancer. 1992;66: 148-54.
12. Chapman MH, Sandanayake NS, Andreola F, Dhar DK, Webster GJ, Dooley JS, et al. Circulating CYFRA 21-1 is a specific diagnostic and prognostic biomarker in biliary tract cancer. J Clin Exp Hepatol. 2011;1: 6-12.
13. Verwaal V, Zoetmulder F. Follow-up of patients treated by cytoreduction and chemotherapy for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol. 2004;30: 280-5.
14. Yang SH, Lin JK, Lai CR, Chen CC, Li A, Liang WY, et al. Risk factors for peritoneal dissemination of colorectal cancer. J Surg Oncol. 2004;87: 167-73.
15. Zheng CX, Zhan WH, Zhao JZ, Zheng D, Wang DP, He YL, et al. The prognostic value of preoperative serum levels of CEA, CA19-9 and CA72-4 in patients with colorectal cancer. World J Gastroenterol. 2001;7: 431-4.
16. Kantoush AA, Ahmed MM, Bushra SS. Evaluation of cyfra 21-1 as a diagnostic tool in lung cancer. J Appl Sci Res. 2009;5: 1195-201.
17. Lumachi F, Marino F, Orlando R, Chiara GB, Basso SMM. Simultaneous multianalyte immunoassay measurement of five serum tumor markers in the detection of colorectal cancer. Anticancer Res. 2012;32: 985-8.
18. Giovanella L, Ceriani L, Giardina G, Bardelli D, Tanzi F, Garancini S. Serum cytokeratin fragment 21. 1 (CYFRA 21. 1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15. 3 (CA 15. 3) and carcinoembryonic antigen (CEA). Clin Chem Lab Med. 2002;40: 298-303.
19. Brechot J, Chevret S, Nataf J, Le Gall C, Fretault J, Rochemaure J, et al. Diagnostic and prognostic value of cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur J Cancer. 1997;33: 385-91.
20. Molina R, Filella X, Auge J, Fuentes R, Bover I, Rifa J, et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Tumor Biol. 2003;24: 209-18.
21. Molina R, Filella X, Augé JM, Bosch E, Torne A, Pahisa J, et al. CYFRA 21. 1 in patients with cervical cancer: comparison with SCC and CEA. Anticancer Res. 2005;25: 1765-71.
22. Jeong S, Park Y, Cho Y, Kim YR, Kim HS. Diagnostic values of urine CYFRA21-1, NMP22, UBC, and FDP for the detection of bladder cancer. Clin Chim Acta. 2012;414: 93-100.
23. Kulpa J, Wójcik E, Reinfuss M, Kołodziejski L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem. 2002;48: 1931-7.
24. Maass J, Hoffmann-Fazel A, Goeroegh T, Hoffmann M, Meyer J, Gottschlich S, et al. Cyfra 21-1: a serological help for detection of distant metastases in head and neck cancer. Anticancer Res. 2000;20: 2241-4.
25. Labianca R, Nordlinger B, Beretta G, Brouquet A, Cervantes A. Primary colon cancer: ESMO clinical practice guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol. 2010;21: v70-7.
26. Scott NA, Wieand HS, Moertel CG, Cha SS, Beart RW, Lieber MM. Colorectal cancer: Dukes' stage, tumor site, preoperative plasma CEA level, and patient prognosis related to tumor DNA ploidy pattern. Arch Surg. 1987;122: 1375-9.
27. Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Investig. 2005;23: 338-51.
28. Sheard MA, Vojtesek B, Simickova M, Valik D. Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis. J Cell Biochem. 2002;85: 670-7.
29. Takada M, Masuda N, Matsuura E, Kusunoki Y, Matui K, Nakagawa K, et al. Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay. Br J Cancer. 1995;71: 160-5.
30. Brockmann JG, Nottberg HS, Glodny B, Heinecke A, Senninger NJ. CYFRA 21-1 serum analysis in patients with esophageal cancer. Clin Cancer Res. 2000;6: 4249-52.
31. Xu D, Li X, Zheng S, Jiang W. Quantitative real-time RT-PCR detection for CEA, CK20 and CK19 mRNA in peripheral blood of colorectal cancer patients. J Zhejiang Univ Sci B. 2006;7: 445-51.
32. Holdenrieder S, Stieber P, Liska V, Treska V, Topolcan O, Dreslerova J, et al. Cytokeratin serum biomarkers in patients with colorectal cancer. Anticancer Res. 2012;32: 1971-6.
33. Wild N, Andres H, Rollinger W, Krause F, Dilba P, Tacke M, et al. A combination of serum markers for the early detection of colorectal cancer. Clin Cancer Res. 2010;16: 6111-21.
34. Uenishi T, Kubo S, Hirohashi K, Tanaka H, Shuto T, Yamamoto T, et al. Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer. Br J Cancer. 2003;88: 1894-9.
35. Kim DW, Kim WH, Kim CG. Dual-time-point FDG PET/CT: is it useful for lymph node staging in patients with non-small-cell lung cancer? Nucl Med Mol Imaging. 2012;46: 196-200.
36. 18F]fluoroethyl)-L-tyrosine PET in patients with suspicious recurrence of glioma after multimodal treatment: initial results of a retrospective comparative study. Nucl Med Mol Imaging. 2010;44: 45-54.